Nuformix (LON:NFX) chairman Dr Chris Blackwell speaks to Proactive following the release of its results to March 2020. He says the focus over the year has been towards the treatment of patients with fibrosis and the development of its anti-fibrotic candidate NXP002. Blackwell adds that he's excited about two new recent revenue generating collaborations they've agreed with Ebers Tech and VistaGen Therapeutics.
Nuformix PLC focused on licensing agreements and further fee-for-service work
Quick facts: Nuformix PLC
Price: 2.75 GBX
Market Cap: £14.12 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Nuformix PLC named herein, including the promotion by the Company of Nuformix PLC in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE